Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234831 · ClinicalTrials.gov registry record · NA
A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 463
- Enrollment target
NCT01234831: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01234831 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 463 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01234831, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 463 participants
- Enrollment target
Study Summary
Methicillin-resistant Staphylococcus aureus (MRSA) is endemic in hospital settings. Colonization with MRSA puts patients at increased risk for invasive infections, and MRSA infections have been associated with high costs and adverse clinic outcomes. Patients can clear MRSA spontaneously. Improved approaches for identifying patients who are no longer colonized are needed; we hypothesize that more sensitive nucleic acid amplification can be used to improve identification of patients who are no longer colonized.
Interventions
- DEVICE nucleic acid amplification of nasal swab; nasal swab culture
- OTHER Nasal swab culture
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 463 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01234831
The ClinicalTrials.gov registry entry for NCT01234831 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 463 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which nucleic acid amplification of nasal swab; nasal swab culture is the first listed.
NCT01234831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01234831 about?
NCT01234831 is a clinical study titled "A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients". Methicillin-resistant Staphylococcus aureus (MRSA) is endemic in hospital settings. Colonization with MRSA puts patients at increased risk for invasive infections, and MRSA infections have been associated with high costs and adverse clinic outcomes. Patients can clear MRSA spontaneously. Improved ap...
What is the current status of trial NCT01234831?
This trial is currently completed. It is a NA study. The enrollment target is 463 participants. The study started on 2010-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01234831?
The interventions under investigation include: nucleic acid amplification of nasal swab; nasal swab culture (DEVICE), Nasal swab culture (OTHER).
Who is sponsoring clinical trial NCT01234831?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.